{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:37:38Z","timestamp":1760060258107,"version":"build-2065373602"},"reference-count":38,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: Electrochemotherapy (ECT) has emerged as a promising locoregional treatment modality for patients with cutaneous and subcutaneous melanoma metastases. While systemic therapies have improved overall disease control, effective local tumor management remains crucial, particularly in oligometastatic or symptomatic disease. This pilot study investigates the role of metabolic imaging with [18F]FDG PET\/CT to assess tumor metabolism in melanoma patients undergoing ECT, building on prior evidence that PET offers valuable functional information beyond anatomical changes detected by conventional imaging. Methods: This retrospective study included 11 patients with histologically confirmed melanoma and cutaneous or subcutaneous metastases treated with ECT. [18F]FDG PET\/CT scans were performed either before ECT, after ECT, or both. Metabolic response was assessed by measuring the tracer uptake (SUVmax) of the ten hottest lesions. Morphological changes were evaluated using CT. Local progression-free survival was determined. Results: A total of 66 lesions were analyzed. Patients with PET\/CT only after ECT showed significantly higher SUVmax and lesion size compared to those imaged before treatment (mean SUVmax: 9.9 \u00b1 11.2 vs. 10.3 \u00b1 5.5; p = 0.034). Progression-free survival differed significantly based on pre-ECT SUVmax values (\u03c72 = 3.90; p = 0.048). Among two patients with follow-up imaging, one showed new lesions on CT with only mild FDG uptake, while the other developed newly FDG-avid metastases after ECT. Conclusions: FDG PET\/CT provides valuable information on tumor viability and treatment response in melanoma patients undergoing ECT, demonstrated by significant differences in metabolic activity between lesions imaged before and after treatment. The lack of longitudinal intra-individual imaging limits definitive conclusions about the direct metabolic effects of ECT.<\/jats:p>","DOI":"10.3390\/cancers17162641","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T09:43:01Z","timestamp":1755078181000},"page":"2641","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metabolic Imaging in Electrochemotherapy: Insights from FDG-PET Analysis in Metastatic Melanoma\u2014A Pilot Study"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3175-952X","authenticated-orcid":false,"given":"Sophie C.","family":"Siegmund","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, LMU University Hospital, LMU Munich, 81377 Munich, Germany"},{"name":"Bavarian Cancer Research Center (BZKF), Partner Site Munich, Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4935-9877","authenticated-orcid":false,"given":"Maximilian","family":"Deu\u00dfing","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, LMU University Hospital, LMU Munich, 80337 Munich, Germany"},{"name":"Department of Dermatology, Allergology and Laser Medicine, Munich Municipal Hospital, 80337 Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolf A.","family":"Werner","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, LMU University Hospital, LMU Munich, 81377 Munich, Germany"},{"name":"The Russell H Morgan Department of Radiology and Radiological Sciences, Division of Nuclear Medicine, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Hartmann","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, LMU University Hospital, LMU Munich, 80337 Munich, Germany"},{"name":"Department of Dermatology, Allergology and Laser Medicine, Munich Municipal Hospital, 80337 Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Kunte","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, LMU University Hospital, LMU Munich, 80337 Munich, Germany"},{"name":"Department of Dermatology and Dermatosurgery, Artemed Fachklinik Munich, 80336 Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s41392-021-00827-6","article-title":"Signal pathways of melanoma and targeted therapy","volume":"6","author":"Guo","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.det.2022.07.017","article-title":"Melanoma classification and management in the era of molecular medicine","volume":"41","author":"Rashid","year":"2023","journal-title":"Dermatol. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.molonc.2011.03.002","article-title":"Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care","volume":"5","author":"Scolyer","year":"2011","journal-title":"Mol. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.21037\/atm.2017.06.09","article-title":"Overcoming resistance to BRAF inhibitors","volume":"5","author":"Arozarena","year":"2017","journal-title":"Ann. Transl. Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Perez, M.C., Tanabe, K.K., Ariyan, C.E., Miura, J.T., Mutabdzic, D., Farma, J.M., and Zager, J.S. (2019). Local and recurrent regional metastases of melanoma. Cutaneous Melanoma, Springer.","DOI":"10.1007\/978-3-319-46029-1_24-1"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/CMR.0b013e32832ac775","article-title":"Skin metastases of malignant melanoma: A clinical and prognostic survey","volume":"19","author":"Savoia","year":"2009","journal-title":"Melanoma Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"104276","DOI":"10.1016\/j.critrevonc.2024.104276","article-title":"The treatment of advanced melanoma: Current approaches and new challenges","volume":"196","author":"Boutros","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/ijd.12346","article-title":"Dermoscopic patterns of cutaneous melanoma metastases","volume":"53","author":"Rubegni","year":"2014","journal-title":"Int. J. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1053\/j.seminoncol.2019.04.002","article-title":"Electrochemotherapy of superficial tumors\u2014Current status:: Basic principles, operating procedures, shared indications, and emerging applications","volume":"46","author":"Campana","year":"2019","journal-title":"Semin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/(SICI)1097-0142(19980701)83:1<148::AID-CNCR20>3.0.CO;2-W","article-title":"Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin","volume":"83","author":"Heller","year":"1998","journal-title":"Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/S0959-8049(98)00025-2","article-title":"Electrochemotherapy with cisplatin: Potentiation of local cisplatin antitumour effectiveness by application of electric pulses in cancer patients","volume":"34","author":"Sersa","year":"1998","journal-title":"Eur. J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"13453","DOI":"10.33263\/BRIAC115.1345313464","article-title":"Analysis of pathways in triple-negative breast cancer cells treated with the combination of electrochemotherapy and cisplatin","volume":"11","author":"Giri","year":"2021","journal-title":"Biointerface Res. Appl. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1111\/bjd.15340","article-title":"Electrochemotherapy in the treatment of metastatic malignant melanoma: A prospective cohort study by InspECT","volume":"176","author":"Kunte","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1111\/jdv.18456","article-title":"Health-related quality of life trajectories in melanoma patients after electrochemotherapy: Real-world insights from the InspECT register","volume":"36","author":"Campana","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Campana, L.G., Peric, B., Mascherini, M., Spina, R., Kunte, C., Kis, E., Rozsa, P., Quaglino, P., Jones, R.P., and Clover, A.J.P. (2021). Combination of Pembrolizumab with Electrochemotherapy in Cutaneous Metastases from Melanoma: A Comparative Retrospective Study from the InspECT and Slovenian Cancer Registry. Cancers, 13.","DOI":"10.3390\/cancers13174289"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1007\/s00259-022-05780-2","article-title":"Joint EANM\/SNMMI\/ANZSNM practice guidelines\/procedure standards on recommended use of [(18)F]FDG PET\/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0","volume":"49","author":"Lopci","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"42","DOI":"10.2174\/1874471012666191009161826","article-title":"Clinical and Prognostic Value of (18)F-FDG-PET\/CT in the Restaging Process of Recurrent Cutaneous Melanoma","volume":"13","author":"Albano","year":"2020","journal-title":"Curr. Radiopharm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1007\/s00330-021-08355-1","article-title":"Prognostic value of total metabolic tumour volume and therapy-response assessment by [(18)F]FDG PET\/CT in patients with metastatic melanoma treated with BRAF\/MEK inhibitors","volume":"32","author":"Annovazzi","year":"2022","journal-title":"Eur. Radiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.2967\/jnumed.111.102566","article-title":"Response assessment using 18F-FDG PET early in the course of radiotherapy correlates with survival in advanced-stage non-small cell lung cancer","volume":"53","author":"Ollers","year":"2012","journal-title":"J. Nucl. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1007\/s00259-017-3703-7","article-title":"Comparison of FDG-PET\/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer","volume":"44","author":"Riedl","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_21","first-page":"96","article-title":"Breslow thickness and (18)F-FDG PET-CT result in initial staging of cutaneous melanoma: Can a cut-off point be established?","volume":"35","year":"2016","journal-title":"Rev. Esp. Med. Nucl. Imagen Mol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"932","DOI":"10.2967\/jnumed.106.035774","article-title":"Partial-volume effect in PET tumor imaging","volume":"48","author":"Soret","year":"2007","journal-title":"J. Nucl. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"358","DOI":"10.2478\/raon-2013-0054","article-title":"Dual time point imaging fluorine-18 flourodeoxyglucose positron emission tomography for evaluation of large loco-regional recurrences of breast cancer treated with electrochemotherapy","volume":"47","author":"Matthiessen","year":"2013","journal-title":"Radiol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1080\/0284186X.2018.1454602","article-title":"Updated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases","volume":"57","author":"Gehl","year":"2018","journal-title":"Acta Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejcsup.2006.08.003","article-title":"Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes","volume":"4","author":"Mir","year":"2006","journal-title":"Eur. J. Cancer Suppl."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ejcsup.2006.08.002","article-title":"Electrochemotherapy\u2013An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study","volume":"4","author":"Marty","year":"2006","journal-title":"Eur. J. Cancer Suppl."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"20190832","DOI":"10.1259\/bjr.20190832","article-title":"Immunotherapy-related adverse effects on (18)F-FDG PET\/CT imaging","volume":"93","author":"Gandy","year":"2020","journal-title":"Br. J. Radiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1158\/1078-0432.CCR-23-2390","article-title":"FDG PET\/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma","volume":"30","author":"Anderson","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1055\/a-1140-5458","article-title":"Textural features in FDG-PET\/CT can predict outcome in melanoma patients to treatment with Vemurafenib and Ipililumab","volume":"59","author":"Dittrich","year":"2020","journal-title":"Nuklearmedizin"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s00262-018-2183-3","article-title":"Longitudinal studies of the (18)F-FDG kinetics after ipilimumab treatment in metastatic melanoma patients based on dynamic FDG PET\/CT","volume":"67","author":"Sachpekidis","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e656","DOI":"10.1097\/RLU.0000000000005440","article-title":"18 F-FDG PET\/CT for Detection of Immunotherapy-Induced Hypophysitis-A Case-Control Study","volume":"49","author":"Fischer","year":"2024","journal-title":"Clin. Nucl. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/RLU.0b013e31828da691","article-title":"Ipilimumab-induced immunomediated adverse events: Possible pitfalls in (18)F-FDG PET\/CT interpretation","volume":"39","author":"Gilardi","year":"2014","journal-title":"Clin. Nucl. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s00259-017-3870-6","article-title":"Absolute number of new lesions on (18)F-FDG PET\/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab","volume":"45","author":"Anwar","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2967\/jnumed.118.213652","article-title":"(18)F-FDG PET\/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma","volume":"60","author":"Ito","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_35","first-page":"357","article-title":"Study of bone cells by confocal microscopy in fractures stimulated by ultrasound","volume":"54","author":"Coman","year":"2013","journal-title":"Rom. J. Morphol. Embryol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.lungcan.2015.05.019","article-title":"FDG-PET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for non-small cell lung cancer","volume":"89","author":"Kohutek","year":"2015","journal-title":"Lung Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s43055-021-00548-4","article-title":"Correlation of primary tumor metabolic parameters with clinical, histopathological and molecular characteristics in breast cancer patients at pre-operative staging FDG-PET\/CT study","volume":"52","author":"AbdElaal","year":"2021","journal-title":"Egypt. J. Radiol. Nucl. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40658-023-00597-w","article-title":"Phantom study and clinical application of total-body (18)F-FDG PET\/CT imaging: How to use small voxel imaging better?","volume":"11","author":"Qi","year":"2024","journal-title":"EJNMMI Phys."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/16\/2641\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:26:13Z","timestamp":1760034373000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/16\/2641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":38,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["cancers17162641"],"URL":"https:\/\/doi.org\/10.3390\/cancers17162641","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2025,8,13]]}}}